The failure of the high-dose regimen to meet exploratory endpoints in the Alzheimer's trial is a significant setback, leading to a 31.4% drop in COYA's stock price. The company's decision to focus on the low-dose regimen, which showed some positive results, may provide a future opportunity, but the immediate impact is negative.